Orotirelin

Summary

Orotirelin is a synthetic TRH analogue developed primarily in Japan as a diagnostic agent for evaluating hypothalamic-pituitary-thyroid axis function. It stimulates TSH and prolactin secretion from the anterior pituitary and has been used to assess spinocerebellar degeneration and thyroid disorders. It has also been investigated for potential neuroprotective and CNS effects.

Mechanism of Action

Synthetic analogue of thyrotropin-releasing hormone (TRH) that binds to TRH receptors in the pituitary gland, stimulating the release of thyroid-stimulating hormone (TSH) and prolactin; used diagnostically to assess pituitary and thyroid function

Routes of Administration

Goals & Uses

• Prolactin stimulation testingEndocrinologyModerate
• Diagnostic evaluation of hypothalamic-pituitary-thyroid axisDiagnosticsHigh
• NeuroprotectionNeurologyLow
• Assessment of spinocerebellar degenerationNeurologyModerate

Contraindications

• HyperthyroidismEndocrineModerate
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Coronary artery diseaseCardiovascularHigh
• Hypersensitivity to orotirelin or TRH analoguesAllergyHigh

Adverse Effects

• Urge to urinateUrologicalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• FlushingVascularCommonWarmth and redness of the skin
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Transient hypotension or hypertensionCardiovascularUncommon

Drug Interactions

• GlucocorticoidsLow
• Thyroid hormones (levothyroxine)Moderate
• Dopamine agonists (bromocriptine, cabergoline)Low

Population Constraints

• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative
• Patients with severe cardiovascular diseaseCardiovascularRelative

Regulatory Status

• European UnionUnapprovedNot approved by the EMA for use in the European Union
• United StatesUnapprovedNot approved by the FDA; not available as a licensed product in the United States
• United KingdomUnapprovedNot approved by the MHRA in the United Kingdom

Approved in Japan as a diagnostic and therapeutic agent. Not approved by the FDA in the United States or by the EMA in Europe.

Evidence & Sources

No sources recorded yet.